Эпизоды
-
While Josh and Michael enjoy a good rambling, meandering podcast as much as the next guy, we made a promise to keep our coverage of the ASCO GU 2024 conference short and sweet. So, as promised, here is the second - and final - episode of our miniseries. For a change of pace, one of our studies involves the adjuvant use of immunotherapy! Specifically, AMBASSADOR looks at pembrolizumab in patients with early urothelial cancer, a patient cohort that is crying out for more effective treatments for early-stage disease. Meanwhile, Josh tries to "BRCAAway" from our comfort zone by discussing the latest trial examining the use of PARP inhibitors in metastatic castration-resistant prostate cancer. Yes, we'll show ourselves out now.
Links to studies discussed in this episode (subscription may be required):
AMBASSADOR (courtesy of ASCO Daily news): https://ascopost.com/news/january-2024/ambassador-pembrolizumab-in-muscle-invasive-and-locally-advanced-urothelial-carcinoma/#:~:text=AMBASSADOR%20(A031501)%20is%20a%20randomized,and%20locally%20advanced%20urothelial%20carcinoma.
BRCAAway (courtesy of urotoday.com): https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137781-asco-2022-brcaaway-a-randomized-phase-2-trial-of-abiraterone-olaparib-or-abiraterone-olaparib-in-patients-with-mcrpc-with-dna-repair-defects.html
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
With Josh's Grand Adventure(TM) now in the books, he and Michael return to their usual programming, examining two studies presented at the not-so-recent ASCO GU conference in San Fransisco. While the conference took place in January of this year, as the old adage goes: better late than never. In this episode, our hosts examine two studies; the CONTACT-02 study examining a combination of immunotherapy + cabozantinib in patients with metastatic castration-resistant prostate cancer, and an update from the KEYNOTE-564 that examined whether pembrolizumab had any benefit in the adjuvant treatment of renal cell cancer. Will either of these studies change practice? Fear not, for our fearless oncological explorers are on hand to guide you through the hazardous ratios and nefarious p values!
Links to studies discussed in this episode via ASCO Daily News(subscription may be required):
CONTACT-02: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.18#:~:text=CONTACT%2D02%20is%20the%20only,Clinical%20trial%20information%3A%20NCT04446117.
KEYNOTE-564: https://dailynews.ascopubs.org/do/keynote-564-adjuvant-pembrolizumab-prolongs-survival-high-risk-clear-cell-renal-cell#:~:text=KEYNOTE%2D564%20is%20the%20first,at%20higher%20risk%20for%20recurrence.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Пропущенные эпизоды?
-
In this episode, Josh interviews the man who helped make this grand adventure possible, his mentor, Professor Elgene Lim of the Kinghorn Cancer Centre in Sydney. Professor Lim is a medical oncologist specialising in breast cancer research. He has previously worked at the Walter and Eliza Hall Institute, completing his PhD under the mentorship of Dr Geoffrey Lindeman and Dr Jane Visvader with research focussed on identifying culprit cells in BRCA1 mutant gene carriers. He subsequently worked with Dr Eric Winer and Dr Myles Brown at the Dana-Farber Cancer Institute and Harvard Medical School. As if this was not enough, Elgene is proud of his volunteer work with asylum seekers and his work with the Asha Kiran Hospital in Orissa, India, in a program of expertise transfer and partnership with local doctors.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Josh interviews Dr Robert Mayer, Professor of Medicine at Harvard Medical School, former director of the Dana Farber Cancer Institute’s Oncology Fellowship Program for 36 years and an expert in gastrointestinal cancer. He founded the Centre for Gastrointestinal Oncology at Dana Farber and has previously chaired the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B. Dr Mayer has also been an associate editor for both the New England Journal of Medicine and the Journal of Clinical Oncology and is a former ASCO president. Bob is the recipient of ASCO’s Distinguished Achievement Award in 2019 and as Josh likes to remind me, a living legend.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Josh interviewed Dr Ann Partridge, the director of the adult survivorship program at the Dana-Farber Institute. She is the co-founder and director of the Program for Young Women with Breast Cancer and is passionate about communication, risk perception and behavioural aspects of cancer care. Dr Partridge is the principal investigator for the Young Women’s Breast Cancer study, which has currently enrolled over 1300 women throughout the United States, and has chaired both ASCO’s scientific program committee and the ESMO-sponsored Breast Cancer in Young Women Conference. In 2018, Dr Partridge was recognized with the American Association for Cancer Research's Outstanding Investigator Award for Breast Cancer Research.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Josh interviews Dr Harold Burstein. A graduate of Harvard University and Harvard Medical School, Dr Burstein’s initial PhD was in cellular immunology. After receiving his oncology fellowship at the Dana Farber Cancer Institute, he joined the staff in 1999. Hal has a particular interest in breast cancer and has participated in national and international clinical trials while also working to develop treatment guidelines worldwide. A passionate educator, Dr. Burstein teaches medical students, residents and fellows at Harvard Medical School and the Dana Farber Cancer Institute.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
Today, on this mid-week special, Oncology for the Inquisitive Mind is delighted to welcome Dr. Jeff Jones, a haematologist, oncologist and the Chief Medical Officer of Cullinan Oncology. Biotech companies are at the forefront of novel drug development, and it is fascinating to take a look behind the curtain and glimpse a small part of how targets are chosen and developed. This includes areas of unmet need, including Exon 20 EGFR mutant lung cancer treatment.
Cullinan Oncology conducts research focused on immuno-oncology and translational cancer medicine, specifically focusing on small molecules and biologics to identify unique targets and develop transformative therapeutics across cancer indications.
Many thanks to Dr Jones and the team at Cullinan for taking the time to appear on our show.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
We return to the Dana Farber Cancer Institute this week as part of our "On the Road" series and interview the multitalented Dr. Geoffrey Shapiro. Dr Shapiro completed his medical training at Cornell University and received his PhD in 1987. His passions lie in early-phase drug development and clinical trials, with a specific flair for cell cycle and DNA repair inhibitor therapeutics. Dr. Shapiro provides an insightful take on drug development, current opportunities, challenges, the world of CDK inhibitors and the future landscape of trials, along with the role of Project Optimus (no, not Optimus Prime!)
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
Today, we interview Dr. Eric Winer, our second guest in our mini-series "On the Road". Dr Winer is no ordinary Oncologist; he is a prolific clinician and researcher, despite being born with haemophilia and living with the consequences of early treatment for this, including HIV. In this episode, OFTIM explores his formative years, challenges and triumphs as he provides unique insights as both a patient and a clinician. This episode was recorded live in front of a captive audience in Sydney, Australia.
Eric is a decorated oncologist who graduated from Yale University School of Medicine and is currently the director of Yale Cancer Centre. He has held many prestigious positions, including the Chair of the American Society of Clinical Oncology and the Chief of the Breast Oncology Program at Dana-Farber Cancer Institute.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
Today, we interview Dr. Erica Mayer as our first guest in the "On the Road" mini-series. Dr. Mayer is a renowned breast cancer oncologist at the Dana Farber Cancer Institute. Each week for the next seven weeks, Michael and Josh will introduce a new guest to share their wealth of experience, expertise and wisdom, covering all the essential topics from career development, mentorship and necessary trials and challenges in the oncology world.
Dr. Mayer graduated from Harvard Medical School and completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Erica is the Director of Breast Cancer Clinical Research and is involved in multiple trials, which she discusses in this interview, along with the role of the PACE trial, CDK 4/6 inhibitors, CT DNA and many other important facets of the breast cancer world.
The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.
The Kinghorn Cancer Centre: https://tkcc.org.au/
Dana Farber Cancer Institute: https://www.dana-farber.org/
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.
Hosted on Acast. See acast.com/privacy for more information.
-
Oncology for the Inquisitive Mind is back, and we have a blockbuster year ahead! Before we get there, we have our year in review 2023. Michael and Josh have poured over the treasure trove of pivotal trials from 2023 to bring you the best studies (in our opinion) from the last 365 days! We used various complex metrics involving no science or maths at all.
Just when you thought you were free from oncology learning, we drag you back in, much like Al Pacino's character from The Godfather is famously quoted saying, "Just when I thought I was out, they pull me back in!". We hope you all have a great year ahead!
Links to studies discussed in this episode (subscription may be required):
5 Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
4 FLAURA2
3 INDIGO
2 MONARCH-E
1 EV-302/KEYNOTE-A39
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
2023 has been a year of highs and lows, a calendar of peaks and troughs, an epoch of mountains and valleys (all right Michael, put the thesaurus away...). From standing ovations for enfortumab vedotin and vorasidenib, to the ongoing black hole that is effective treatments for pancreatic and hepatocellular carcinomas. However, through it all the brightest minds in the field have continued to stoke the fires of hope with the development of novel antibody-drug conjugates, immunotherapies and clever applications of established treatments.
How fitting, then, that Josh and MIchael - definitely NOT amongst the brightest minds in the field, but two of the most enthusiastic - end their coverage of 2023 with a final glance into the future of lung cancer treatment. Keeping themselves to a (not so) strict five minute limit, they will look at four studies that may offer a glimpse into how lung cancer of both the small- and non-small cell variety may be managed.
We wish you a very happy and safe New Year, and a happy beginning to 2024.
Links to studies discussed in this episode (subscription may be required):
DS-7300: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDQwMw==
ETER701: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDgwNQ==
INTELLECT: https://pubmed.ncbi.nlm.nih.gov/36829154/
HERTHENA-Lung01: https://ascopubs.org/doi/full/10.1200/JCO.23.01476
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Additional sound effects courtesy of Pixabay: https://pixabay.com/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
ASCO and ESMO are done, and soon, 2023 itself will be in the rearview mirror. And yet, there are still conferences happening around the world; yes, we know the World Conference on Lung Cancer occurred before ESMO, but there is such a thing as too much of a good thing. Join Michael and Josh on their latest virtual journey abroad, this time to the equatorial island of Singapore, as they report on two of their favourite studies from WCLC 2023. For those who celebrate, have a Merry Christmas and a happy festive season.
Links to studies discussed in this episode (subscription may be required):
MARS-2: https://pubmed.ncbi.nlm.nih.gov/32873681/
FLAURA2: https://www.nejm.org/doi/full/10.1056/NEJMoa2306434
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
On this episode, their final of 2023, Michael and Josh return to the world of recent fan favourite, enfortumab vedotin (EV). Not content to sing its praises from every rooftop, our intrepid hosts take the necessary step of examining the common and sometimes severe manifestations of dermatological toxicity deriving from EV. With the assistance of a recently published guideline, they examine the presentation, assessment and management of skin toxicity.
From all of us at OftiM, we would like to thank you for joining us throughout 2023, and we wish you a very happy festive season.
Useful Links:
Guideline ( et al, 2023): https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.19454
CTCAE 5.0 guidelines for skin toxicity: https://www.researchgate.net/figure/Folliculitis-example-of-an-existing-toxicity-in-CTCAE_fig3_323714281
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space. However, the fight of the world's oncologists continues across all fronts, and TNBC is no different. In today's episode, Michael and Josh will discuss the twin pillars of modern anti-cancer therapies: antibody-drug conjugates (sacituzumab govitecan) and immunotherapy (pembrolizumab). As so often the case, this is a growth area of medical oncology and one that we are very excited to (finally) address.
Links to studies discussed in this episode (subscription may be required):
ASCENT: https://www.nejm.org/doi/full/10.1056/NEJMoa2028485KEYNOTE-355: https://www.nejm.org/doi/full/10.1056/NEJMoa2202809For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
For patients with advanced cancer, early-phase trials may represent the last best hope of significant anticancer response. For clinicians, every early phase trial holds virtually unlimited promise and hope of becoming the next immunotherapy or hot antibody-drug conjugate. However, early-phase trials also come with significant uncertainty of efficacy, toxicity and even dosing.
A recent Limbic article (link below) reported on an article published in ESMO Open that investigated the burden of "time toxicity" for patients enrolled in early-phase clinical trials, and advocated for this to be minimised. While it is essential to consider logistic factors and patient preferences, early-phase trials are frequently more inflexible compared to phase II or III studies, and are constructed as such to ensure patient safety in the face of significant unknowns.
In this episode of Fireside Chats, Michael and Josh discuss the pros and cons of attempting to streamline early phase trials, if it is possible, and what can be done to minimise a trial's impact on a patient's day-to-day and quality of life.
Article discussed in this episode (subscription may be required):
"‘Time toxicity’ burden for patients in early phase cancer trials," by Siobhan Calafiore
Available from: https://thelimbic.com/oncology/time-toxicity-burden-for-patients-in-early-phase-cancer-trials/?utm_source=sfmc&utm_medium=email&utm_campaign=Onc%201.12.23&utm_term=Read%20more&utm_id=91262&uid=12231&lk=0d144a028ccc3d800f567af6e9fa7662
Art courtesy of Taryn Silver
Audio courtesy of:
Olexy on pixabay: https://pixabay.com/users/olexy-25300778/JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.
Hosted on Acast. See acast.com/privacy for more information.
-
San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, the research and vibrant discussions did not disappoint, with updates, controversies and complexities. Taking centre stage were PIK3CA mutation treatments, updates on CDK4/6 inhibitors and the age-old question - does exercise improve outcomes for our patients?
Studies discussed in today's episode (subscription may be required)
MONARCH-3KATHERINEINAVO120PREFERABLE EFFECTFor more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lung Cancer world with new drugs (amivantamab and lazertinib) to treat patients hose who progressed on osimertinib. The second trial is the EV-302/KEYNOTE-A39, which explores whether enfortumab vedotin (ADC) and pembrolizumab (immunotherapy) can best-platinum-based chemotherapy. No prior trial has ever done this, so the stakes are high. As the little engine once said, "I think I can", and, we, too, continue to see seismic shifts in cancer treatment in our quest for better therapy.
For now, the OFTIM team is signing out and taking a small break after daily reporting, but we hope you loved it and can't wait to return with more from the fascinating world of Medical Oncology.
Studies
EV-302/KEYNOTE-A39 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639614
MARIPOSA-2 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639283
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired in the pre-immunotherapy and pre-targeted therapy ages, ESMO brought some much-needed positive trials in the areas of cervical cancer, as well as an interesting (albeit negative) study of the PARP-inhibitor olaparib that highlights some of the more practical challenges of running an international phase 3 study. As always, outcomes can always improve, but any progress in this very important area is always a welcome development.
Studies discussed in this episode (subscription may be required):
A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639091innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639430Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639154For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
-
Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatous skin cancers. Cemiplimab is now a standard of care for patients with locally advanced, unresectable or metastatic cSCC, and is particularly effective in patients with cancer driven by UV-induced DNA damage. However, oncologists and researchers are always looking for new and better ways to use established treatments. At ESMO 2023 two papers took this approach; one examined moving immunotherapy to the neoadjuvant space, while another added a venerable EGFR inhibitor to treatment of advanced cSCC. However, the undoubted star of this show is the long-term results of tebentafusp, the first efficacious treatment of a subtype of the notorious uveal melanoma. ESMO 2023 truly had something for everyone, and the melanoma and skin cancer areas were no exception.
Studies discussed in today's episode (subscription may be required)
A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up. https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638272 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639251A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638271For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
- Показать больше